Confronto
DSIP vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
62568-57-4
396091-73-9
Peso molecolare
848.81 g/mol
1047.21 g/mol
Emivita
0.1 h
nessun dato
Sequenza
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glunessun dato
Meccanismo d'azione
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
1
1
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between DSIP and Pasireotid?
- DSIP is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Pasireotid?
- The highest available evidence level is "Studio sull'uomo" for DSIP and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Pasireotid in Germany and the United States?
- Germania: DSIP — Non approvato, Pasireotid — Su prescrizione. Stati Uniti: DSIP — Non approvato, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.